The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.
November 26th 2024
The investigators of this study noted an association between obesity and conditions such as rosacea, psoriasis, and lichen simplex chronicus.
November 22nd 2024
November 19th 2024
Are Medicare Patients Waiting Too Long for Melanoma Removal?
April 27th 2015Most oncologists recommend removing melanomas within 4 to 6 weeks of diagnostic biopsy. Researchers have analyzed Medicare's database to determine how quickly the highest risk population (elderly people) have melanomas removed. Their findings indicate 20 percent wait more than 1.5 months to have the malignancy removed, and roughly 8 percent wait longer than 3 months.
Momentum for a Melanoma Marker Modality
April 22nd 2015Any clinician who biopsies multiple melanocytic lesions per day daydreams about a modality that will consistently and accurately distinguish the neoplasms that haunt us the most: the ones with no clear diagnosis. New diagnostic technology may soon make that dream a reality.
Guttate Psoriasis As a Prognostic Marker for Plaque Psoriasis
The first guttate psoriasis (GP) episode, which is often triggered by an acute infection such as streptococcal pharyngitis, often results in patients developing chronic plaque psoriasis, according to research presented at the 73rd American Academy of Dermatology Annual Meeting.
Young Man with a Rash on His Chest
April 8th 2015This 29-year-old man came in for a wellness evaluation but notes having had this rash for 8 years. Occasionally it itches, but otherwise is asymptomatic and he has had no treatment for it to date. He does not take any medications and has no significant past medical history.
Treatment of Plaque Psoriasis Taking Big Steps Forward Part 2
While several new treatment options for plaque psoriasis and psoriatic arthritis have launched in recent years, there is still much work to be done in the field to help patients through long stretches of care.
New Medication Shows Early Promise for Psoriasis Patients Part 2
A lot of work goes into a medication being approved for the public including many rounds of trials and adjustments along the way. For a new plaque psoriasis medication that work is well underway and the developers hope to have it to patients in the near future.
New Medication Shows Early Promise for Psoriasis Patients
The development of new medications to help patients with plaque psoriasis seems to take steps forward on a daily basis. Results presented at a recent conference showed at least one could help provide much needed relief for this patient group.
Investigating Melanoma Rates in Asian and Hispanic Populations
Whether it is sitting at the beach, working in the yard or just walking to the grocery store, the risk of developing skin cancer is a risk for everyone. A recent study looked at the impact of the sun particularly for asian and hispanic people.
Stelara Recommended to Treat Psoriatic Arthritis in the United Kingdom
The National Institute for Health and Care Excellence in United Kingdom has recommended Janssen's Stelara for the treatment of psoriatic arthritis, adding to its recommendation of the drug already to treat plaque psoriasis.
New Test Could Clear Up Some Melanoma Diagnoses
In most instances a microscope is enough to make a diagnosis of melanoma, but in some the view under the lens does not provide a clear enough picture. A new test that combines math and science could make the most difficult cases easier to identify.
Shingles Vaccine Provides Benefits Without Much Risk
For anyone who has had or been exposed to someone with chicken pox herpes zoster, or shingles, can be a very real risk. A vaccine for patients over the age of 60 can greatly reduce the likelihood of contracting the disease.
Plaque Psoriasis: Cosentyx Continues to Come Out on Top
Novartis announced results from the CLEAR study demonstrating Cosentyxâ„¢ (secukinumab) improved skin clearance at Week 16 in significantly more moderate-to-severe plaque psoriasis patients compared to Stelara®* (ustekinumab), a widely used biologic.